>
>
CAMBRIDGE, Mass., May 25, 2022 (GLOBE NEWSWIRE) — Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that
On track to initiate two parallel adequately-powered Phase 2 trials of emraclidine in schizophrenia by mid-year 2022 Data for the darigabat Phase 2 proof-of-concept trial
CAMBRIDGE, Mass., April 13, 2022 (GLOBE NEWSWIRE) — Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced
Oral presentation to highlight preclinical data demonstrating robust antiepileptic activity for darigabat in drug-resistant focal epilepsy Poster presentations to include further evidence of tavapadon’s consistent
CAMBRIDGE, Mass., March 21, 2022 (GLOBE NEWSWIRE) — Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that
Announced positive results from Phase 1 healthy volunteer trial of darigabat in acute anxiety On track to initiate two parallel adequately-powered Phase 2 trials of
CAMBRIDGE, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) — Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced
In healthy volunteers, both the 7.5 mg and 25 mg twice-daily doses of darigabat demonstrated a clinically meaningful and statistically significant improvement in the Panic
Emraclidine now the international nonproprietary name (INN) for CVL-231, an M4-selective positive allosteric modulator in development for schizophrenia Company expects to initiate Phase 2
CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) — Cerevel Therapeutics (Nasdaq: CERE), a global company dedicated to unraveling the mysteries of the brain to
